Factors that might cause such a difference include, but that are not limited to, those discussed in our quarterly and annual reports filed with the SEC. Copies of these documents are available upon request from Investor Relations at Senomyx or may be accessed via our website at www.senomyx.com.
I’d now like to turn the discussion over to Kent Snyder, CEO of Senomyx.
Thank you, Gwen. Good morning to everyone, and thank you for joining the Senomyx management team for our conference call and webcast. During this call, we’ll provide you with a general business and financial update for the third quarter of 2011, and this will be followed by a question-and-answer session.During the past quarter, Senomyx has continued to make important strides both on the commercial and discovery and development fronts. As John will discuss in more detail later in the call, we are very encouraged by Firmenich’s progress and their commitment regarding their commercialization activities for our S6973 sucrose enhancer. S6973 is a unique ingredient that allows sucrose to be reduced in numerous products by up to 50% while maintaining the desired taste of natural sugar. We are excited that major food and beverage companies have achieved positive consumer acceptance of testing results with products that contain S6973. Firmenich has been notified of client’s plans to launch reformulated established brands that incorporate S6973 in North and South America starting in the first quarter of 2012, and we expect continued launches throughout the year. We’re also pleased with Firmenich’s marketing activities with Senomyx’s S2383 Sucrose Enhancer. S2383 can be used to enable up to a 75% reduction in the concentration of the artificial sweetener Sucralose in foods and beverages with improved taste characteristics and some applications. Client feedback from top chef companies regarding S2383 continues to be positive and Firmenich has expanded the geographic scope of their commercialization effort from North America into Latin America.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV